These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
144 related items for PubMed ID: 24164572
21. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Diabetes Obes Metab; 2008 Nov; 10(11):1057-61. PubMed ID: 18422675 [Abstract] [Full Text] [Related]
22. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Gómez-Lechón MJ, Castell JV, Donato MT. Chem Biol Interact; 2007 May 20; 168(1):30-50. PubMed ID: 17134688 [Abstract] [Full Text] [Related]
23. Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. Greene RJ, Tu H, Gibbs JP, Greg Slatter J. Xenobiotica; 2011 Nov 20; 41(11):945-57. PubMed ID: 21867423 [Abstract] [Full Text] [Related]
24. Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching. Leblanc A, Shiao TC, Roy R, Sleno L. Rapid Commun Mass Spectrom; 2010 May 15; 24(9):1241-50. PubMed ID: 20391594 [Abstract] [Full Text] [Related]
25. Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. Holmgren G, Sjögren AK, Barragan I, Sabirsh A, Sartipy P, Synnergren J, Björquist P, Ingelman-Sundberg M, Andersson TB, Edsbagge J. Drug Metab Dispos; 2014 Sep 15; 42(9):1401-6. PubMed ID: 24980256 [Abstract] [Full Text] [Related]
26. Metabolites and safety: What are the concerns, and how should we address them? Smith DA, Obach RS. Chem Res Toxicol; 2006 Dec 15; 19(12):1570-9. PubMed ID: 17173370 [Abstract] [Full Text] [Related]
27. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Uetrecht JP. Drug Metab Rev; 1992 Dec 15; 24(3):299-366. PubMed ID: 1628536 [Abstract] [Full Text] [Related]
30. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Wang WW, Khetani SR, Krzyzewski S, Duignan DB, Obach RS. Drug Metab Dispos; 2010 Oct 15; 38(10):1900-5. PubMed ID: 20595376 [Abstract] [Full Text] [Related]
32. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D. Drug Metab Dispos; 2009 Mar 15; 37(3):536-44. PubMed ID: 19074975 [Abstract] [Full Text] [Related]
34. Protocols of in vitro protein covalent binding studies in liver. Lévesque JF, Day SH, Jones AN. Methods Mol Biol; 2011 Mar 15; 691():283-301. PubMed ID: 20972760 [Abstract] [Full Text] [Related]
36. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Meanwell NA. Chem Res Toxicol; 2011 Sep 19; 24(9):1420-56. PubMed ID: 21790149 [Abstract] [Full Text] [Related]
38. Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Fukuda H, Ohashi R, Tsuda-Tsukimoto M, Tamai I. Drug Metab Dispos; 2008 Jul 19; 36(7):1275-82. PubMed ID: 18388177 [Abstract] [Full Text] [Related]